- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Biosyent Inc. (RX)
Biosyent Inc. stock price live, this page displays TSXV RX stock exchange data. View the RX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Biosyent Inc. real time stock price chart below.
What Is the Biosyent Inc. Stock Price Today?
The Biosyent Inc. stock price today is 12.80.
What Is the Stock Symbol for Biosyent Inc.?
The stock symbol for Biosyent Inc. is "RX."
What Stock Exchange Does Biosyent Inc. Trade On?
Biosyent Inc. is listed and trades on the TSXV stock exchange.
Is Biosyent Inc. a Good Stock to Buy?
Determining whether Biosyent Inc.—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RX quote. (ISIN: CA0906901081)
What Is the Biosyent Inc. Stock Price Today?
The Biosyent Inc. stock price today is 12.80.
What Is the Stock Symbol for Biosyent Inc.?
The stock symbol for Biosyent Inc. is "RX."
What Stock Exchange Does Biosyent Inc. Trade On?
Biosyent Inc. is listed and trades on the TSXV stock exchange.
Is Biosyent Inc. a Good Stock to Buy?
Determining whether Biosyent Inc.—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RX quote. (ISIN: CA0906901081)
12.80
-1.00(-7.25%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.66
13.60
52 wk Range
9.20
14.20
RX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.6613.60
52 wk Range
9.2014.20
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.72%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.72%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
RX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
13.50
Upside
+5.47%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Holds more cash than debt on its balance sheet
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Biosyent Inc. Company Profile
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. BioSyent Inc. was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. The company was founded in 2006 and is headquartered in Mississauga, Canada.
Biosyent Inc. Earnings Call Summary for Q3/2025
- BioSyent reported Q3 2025 revenue of CAD 12M (up 28% YoY) and net income of CAD 2.7M (up 16%), marking its 61st consecutive profitable quarter despite a slight stock dip of 0.28%.
- EBITDA rose 27% to CAD 3.6M with a 30% margin, while year-to-date revenue reached CAD 33M, reflecting 27% growth compared to the previous year.
- The company projects trailing twelve-month revenue to exceed CAD 42M by year-end and maintains a strong cash position of CAD 27.5-29M for future acquisitions and product launches.
- BioSyent plans to launch a new endocrinology asset in Q1 2027 and is actively exploring in-licensing and M&A opportunities to diversify its portfolio while maintaining its market leadership in iron supplements.
- CEO René Goehrum highlighted the company's dual focus on reinvesting in innovation while returning capital to shareholders, noting no dilutive share options have been issued in 5.5 years.
Last Updated: 2025-11-20, 06:58 p/m
Read Full TranscriptCompare RX to Peers and Sector
Metrics to compare | RX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 16.7x | −2.4x | −0.5x | |
PEG Ratio | 0.67 | 0.01 | 0.00 | |
Price/Book | 3.6x | 0.2x | 2.6x | |
Price / LTM Sales | 3.4x | 0.7x | 3.3x | |
Upside (Analyst Target) | 5.5% | 118.2% | 45.7% | |
Fair Value Upside | Unlock | 15.5% | 6.5% | Unlock |
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 13.50
(+5.47% Upside)
Earnings
Latest Release
Nov 20, 2025
EPS / Forecast
0.23 / --
Revenue / Forecast
12.22M / 9.80M
People Also Watch
FAQ
What Is the Biosyent Inc. (RX) Stock Price Today?
The Biosyent Inc. stock price today is 12.80
What Stock Exchange Does Biosyent Inc. Trade On?
Biosyent Inc. is listed and trades on the TSX Venture Exchange.
What Is the Stock Symbol for Biosyent Inc.?
The stock symbol for Biosyent Inc. is "RX."
Does Biosyent Inc. Pay Dividends? What’s The Current Dividend Yield?
The Biosyent Inc. dividend yield is 1.72%.
What Is the Biosyent Inc. Market Cap?
As of today, Biosyent Inc. market cap is 144.17M.
What Is Biosyent Inc.'s Earnings Per Share (TTM)?
The Biosyent Inc. EPS (TTM) is 0.75.
When Is the Next Biosyent Inc. Earnings Date?
Biosyent Inc. will release its next earnings report on Mar 18, 2026.
From a Technical Analysis Perspective, Is RX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Biosyent Inc. Stock Split?
Biosyent Inc. has split 0 times.
What is the current trading status of Biosyent Inc. (RX)?
As of Feb 07, 2026, Biosyent Inc. (RX) is trading at a price of 12.80, with a previous close of 13.80. The stock has fluctuated within a day range of 12.66 to 13.60, while its 52-week range spans from 9.20 to 14.20.
What Is Biosyent Inc. (RX) Price Target According to Analysts?
The average 12-month price target for Biosyent Inc. is CAD13.50, with a high estimate of CAD13.5 and a low estimate of CAD13.5. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +5.47% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.